Protara Therapeutics, Inc. — Director's Dealing 2019

Jan 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2018-12-31

Reporting Person: Kowalsky Matthew Paul (VP, Legal and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-31	Common Stock	A	2448	$1.93	Acquired	29479	Direct

Footnotes

F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2018 through December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).